May 13, 2020 / 10:27 PM / 21 days ago

BRIEF-Janssen's BCMA CAR-T Therapy JNJ-4528 Showed Early Responses In Heavily Pretreated Patients With Multiple Myeloma

May 13 (Reuters) - Johnson & Johnson:

* JANSSEN’S BCMA CAR-T THERAPY JNJ-4528 SHOWED EARLY, DEEP AND DURABLE RESPONSES IN HEAVILY PRETREATED PATIENTS WITH MULTIPLE MYELOMA

* JANSSEN PHARMACEUTICAL - LONGER-TERM FOLLOW-UP DATA FROM PHASE 1B/2 CARTITUDE-1 STUDY DEMONSTRATE 100% OVERALL RESPONSE RATE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below